tumor microenvironment

Targeting neoantigens in multiple myeloma with CAR T-cell 5:56
Targeting neoantigens in multiple myeloma with CAR T-cell
Angela Krackhard • 6 Apr 2022
Unanswered questions in developing engineered T cells for solid tumors 2:35
Unanswered questions in developing engineered T cells for solid tumors
Elvira D’Ippolito • 31 Mar 2022
Trends and innovations within the advanced therapy sector 1:12
Trends and innovations within the advanced therapy sector
Bruce Levine • 27 Jan 2022
Mechanisms of resistance to CAR T-cell therapies 5:09
Mechanisms of resistance to CAR T-cell therapies
John Rossi • 26 Aug 2021
Genome editing to address challenges with adoptive T-cell therapy 3:02
Genome editing to address challenges with adoptive T-cell therapy
Chiara Bonini • 22 Nov 2021
Developing novel TCR-based T cell products for cancer therapy 3:13
Developing novel TCR-based T cell products for cancer therapy
Chiara Bonini • 22 Nov 2021
Liquid vs solid tumor strategies in cell therapy 2:17
Liquid vs solid tumor strategies in cell therapy
Kanya Rajangam • 13 Oct 2021
The landscape of cell therapy for solid tumors 1:22
The landscape of cell therapy for solid tumors
Sven Kili • 5 Oct 2021
Selecting TCRs: understanding peptide-HLA-TCR interactions 6:05
Selecting TCRs: understanding peptide-HLA-TCR interactions
Dolores Schendel • 25 Feb 2021
Combining iNKT and CAR technology 6:34
Combining iNKT and CAR technology
Marc van Dijk • 23 Feb 2021
PD1-41BB switch receptor expression in the treatment of PD-L1-positve solid tumors 5:11
PD1-41BB switch receptor expression in the treatment of PD-L1-positve solid tumors
Dolores Schendel • 25 Feb 2021
The content of VJRegenMed is intended for healthcare professionals